Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study)

Author:

Bazzan M1,Vaccarino A1,Stella S2,Sciascia S3,Montaruli B4,Bertero M T5,Carignola R6,Roccatello D3,

Affiliation:

1. Haematology and Thrombosis Unit, San Giovanni Bosco Hospital, Torino, Italy

2. Immunohematology and Transfusion Medicine, San Giovanni Bosco Hospital, Torino, Italy

3. Immunopathology and Rare Diseases Unit, University of Turin; San Giovanni Bosco Hospital, Torino, Italy

4. Haemostasis Laboratory, Umberto I Hospital, Torino, Italy

5. Clinical Immunology, Umberto I Hospital, Torino, Italy

6. Internal Medicine, San Luigi Gonzaga Hospital, Torino, Italy

Abstract

Background Patients with antiphospholipid syndrome (APS) often have thrombotic recurrences, sometimes despite appropriate ongoing anticoagulant treatment. Identifying APS vascular patients at high risk for thrombotic recurrences is still an unsolved issue. Objectives To report the real-life experience of thrombotic recurrences in APS patients included in the Piedmont observational cohort study, and evaluate clinical and laboratory risk factors for thrombotic recurrences. Patients A multi-centre observational study was performed by enrolling 177 patients with vascular APS (primary APS in 99 subjects (56%)); the median follow-up was five years (range 1–26 years). Results The observed thrombotic recurrence rate was about 7.5/100 patient years in the first five years after the first thrombotic event. While the first recurrence often occurred (45%) in patients who were not on oral anticoagulant therapy (OAT), the second recurrence mainly occurred despite ongoing OAT (80%). However, due to the real-life observational nature of this study, treatment was based on the treating physician’s judgement, and no structured therapeutic protocol was applied. Moreover, compliance with OAT was not available. No differences in antiphospholipid antibodies (aPL) profile were observed between patients with or without thrombotic recurrences, but a high risk aPL profile (Miyakis type 1 and 2a) was present in 96% of our patients, 26% of whom had triple positivity. Diabetes ( p < 0.01, OR 10), inherited thrombophilia ( p < 0.0078, OR 4) and OAT withdrawal were independent risk factors for recurrences. Conclusions With the limit of a real-life observational cohort study, the thrombotic recurrence rate in APS was as high as 7.5/100 patient years in the first five years after the first thrombotic event. OAT discontinuation, diabetes and inherited thrombophilia, when associated with a high-risk aPL profile, are risk factors for thrombotic recurrences.

Publisher

SAGE Publications

Subject

Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3